PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients
Abstract Objective To investigate the frequency of PD-1 and LAG-3-positive T cells in relapsed/refractory multiple myeloma (RRMM) patients and its clinical significance. Methods This prospective observational study enrolled a total of 71 RRMM patients, as well as 70 MM patients (non-refractory) and...
Main Authors: | Ming Chen, Jinlian Zhu, Xuedong Yang, Jianxin Yao, Yuqing Liu, Qiang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | European Journal of Medical Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40001-022-00923-5 |
Similar Items
-
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01) -
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01) -
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01) -
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01) -
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)